Table 4.
Effects of Different Concentrations of MP and FK506 on cccDNA in HepG2.2.15 Cells (n=3)
| |
|
HBV cccDNA (copies/mL) |
||
|---|---|---|---|---|
| Medication | Concentration (μg/L) | 24 h | 48 h | 72 h |
| MP | 0(1) | 6.9279±0.0278 | 6.9480±0.0119 | 6.8164±0.0752 |
| MP | 10(2) | 6.2319±0.4287 | 5.9526±0.0454 | 5.8975±0.0295 |
| MP | 50(3) | 6.1858±0.7162 | 5.5906±0.1751 | 5.7471±0.0524 |
| MP | 100(4) | 5.7439±0.8762 | 5.5800±0.0979 | 5.1162±0.0038 |
| MP | 250(5) | 5.1583±0.3957 | 5.1427±0.3142 | 4.8272±0.0364 |
| F | 3.956* | 49.283** | 842.499** | |
| r | −0.762 | −0.902 | −0.972 | |
| p | 0.001 | 0.000 | 0.000 | |
| FK506 | 0(1) | 6.2142±0.1357 | 6.3327±0.0224 | 6.3972±0.0824 |
| FK506 | 50(2) | 5.9847±0.1808 | 5.9449±0.2451 | 6.4222±0.1501 |
| FK506 | 100(3) | 6.0663±0.0502 | 5.8854±0.2664 | 5.7476±0.3293 |
| FK506 | 500(4) | 5.59033±0.0449 | 5.6382±0.4164 | 5.5517±0.6007 |
| F | 3.791 | 3.251 | 4.790 | |
*
p<0.05; **p<0.01.
HepG2.2.15 cells were treated with different concentrations of MP and FK506. The cccDNA levels were significantly decreased by MP in a concentration-dependent (but time-independent) manner compared with the control group (r=−0.957, −0.927, −0.917; p≤0.001). FK506 had no inhibitory effect on cccDNA replication in vitro (p>0.05).
MP, methylprednisolone; FK506, tacrolimus; HBV, hepatitis B virus; cccDNA, covalently-closed circular DNA.